Latest News
Avidity Biosciences announces US Managed Access Program for delpacibart zotadirsen (del-zota)
20 November 2025 - Biopharmaceutical company Avidity Biosciences Inc (Nasdaq:RNA) announced on Wednesday its Managed Access Program (MAP) for investigational therapy delpacibart zotadirsen (del-zota) for eligible people with Duchenne muscular dystrop...
Nuvalent's zidesamtinib NDA filing accepted by US FDA
20 November 2025 - Clinical-stage biopharmaceutical company Nuvalent Inc (Nasdaq:NUVL) said on Wednesday that the US Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for zidesamtinib, an investigational ROS1-s...
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
20 November 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX: 01801) announced on Wednesday that the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in C...
Frost & Sullivan honours WuXi AppTec
20 November 2025 - Business consulting company Frost & Sullivan announced on Wednesday that WuXi AppTec has been awarded the 2025 Global Company of the Year Recognition in the contract research, development, and manufacturing organisation (CRDMO)...
Hemispherian secures US patent allowance expanding GLIX1 patent protection
19 November 2025 - Norwegian biotechnology company Hemispherian AS announced on Wednesday that the US Patent and Trademark Office has issued a Notice of Allowance for its patent application covering use of its lead clinical candidate, GLIX1, in cance...